Please assess the completion status of the following clinical trial:

Trial Title: Clinical Study With Blinatumomab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with Diffuse Large B-Cell Lymphoma (DLBCL) who are refractory to first or later treatment or have a first relapse or later relapse not eligible for autologous hematopoietic stem cell transplant (HSCT) or relapsed post- autologous-HSCT~* Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2~* Age ≥ 18 years~* Life expectancy of ≥ 12 weeks~* Cerebrospinal fluid (CSF) free of infiltration by DLBCL~Exclusion Criteria:~* History or presence of clinically relevant central nervous system (CNS) pathology as epilepsy, seizure, paresis, aphasia, stroke, severe brain injuries, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, psychosis~* Current infiltration of CSF by DLBCL~* History of autoimmune disease with potential CNS involvement or current autoimmune disease~* Autologous HSCT within six weeks prior to start of blinatumomab treatment~* Prior allogeneic HSCT~* Cancer chemotherapy within two weeks prior to start of blinatumomab treatment~* Radiotherapy within four weeks prior to start of blinatumomab treatment~* Immunotherapy (e.g., rituximab) within four weeks prior to start of blinatumomab treatment~* Any investigational anti-lymphoma product within four weeks prior to start of blinatumomab treatment~* Treatment with any other investigational product after signature of informed consent~* Known hypersensitivity to immunoglobulins or to any other component of the study drug formulation~* Abnormal laboratory values indicative of inadequate renal or liver function~* History of malignancy other than non-Hodgkin's lymphoma (NHL) within five years prior to start of blinatumomab treatment with the exception of basal cell or squamous cell carcinoma of the skin, or carcinoma in situ of the cervix~* Active uncontrolled infection, any other concurrent disease or medical condition that is deemed to interfere with the conduct of the study as judged by the investigator~* Infection with human immunodeficiency virus (HIV) or chronic infection with hepatitis B virus or hepatitis C virus~* Pregnant or nursing women~* Previous treatment with blinatumomab~* Presence of human anti-murine antibodies (HAMA) at screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Blinatumomab (Type: EXPERIMENTAL): By study design, two dose regimens were assessed in this study. In Stage 1, Cohort 1, participants received blinatumomab in a dose-escalating manner: 9 µg/day for the first week, followed by 28 µg/day for the second week, then 112 µg/day for the remaining 6 weeks of treatment during cycle 1. In Cohort 2, the next participants enrolled and received a constant dose of 112 µg/day blinatumomab. The dosing regimen with the more favorable benefit-risk profile was then selected for Stage 2, Cohort 3.

Based on this trial design, predict the completion outcome and termination type (if applicable).